NIH-Funding

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional)

NIH Funding Announcements - Mon, 12/18/2017 - 11:35
Funding Opportunity PA-18-348 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.
Categories: NIH-Funding

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21 Clinical Trial Optional)

NIH Funding Announcements - Mon, 12/18/2017 - 11:35
Funding Opportunity PA-18-347 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.
Categories: NIH-Funding

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R15 Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 11:35
Funding Opportunity PA-18-473 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline. There is particular interest in interventions that can be implemented in community settings by the affected individual, informal caregivers, or others in the community. Research to inform the development of such interventions is also of interest, as well as research examining underlying mechanisms and biomarkers associated with response to interventions. It is anticipated that the results of this research will help affected individuals maintain independence and quality of life, improve their ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs), and additionally help to reduce stress, burden, and other poor outcomes in their caregivers.
Categories: NIH-Funding

Health-professional Education Partnership Initiative (HEPI) (R25 Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 11:07
Funding Opportunity RFA-TW-17-001 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this Fogarty International Center R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs by enhancing health workforce capacity in high HIV-burden, low-income countriesin sub-Saharan Africa; enhance the diversity of the biomedical, behavioral and clinical research workforce by encouraging interprofessional education initiatives to enhance team health care delivery; help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences in low-income countries to enhance capacity of US research projects; foster a better understanding of biomedical, behavioral and clinical research and its implications to improve capacity to develop, implement and evaluate evidence-based health services. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on courses for Skills Development;Research training; Mentoring Activities; Curriculum or Methods Development to increase Outreach to broad communities to enhance participation in skills development courses, curricula, and mentoring activities.
Categories: NIH-Funding

By: uso

WriteEdit-Grant Questions Blog - Mon, 12/18/2017 - 10:51

thank you so much

Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Mon, 12/18/2017 - 10:47

You can sit tight – nothing has gone wrong, other than bureaucracy during the holiday period, when everything takes a little longer (especially with all the FY18 federal budget chaos as well). Once the grants management folks have finished preparing the awards, they still need to be signed off on. If the GMS needed any more information from you, they would have gotten in touch directly. Just be patient a little longer – no need to be worried (and congratulations!).

Categories: NIH-Funding

By: uso

WriteEdit-Grant Questions Blog - Mon, 12/18/2017 - 10:03

My application for R01 funding to NHLBI received a score of 11% in June 2017. I have submitted requested JIT information, and status on era commons has switched to “pending”. The grants management specialist told me that the NOA was set to be released on 12/12/2017 but I still have not heard anything. I don’t want to keep bugging them – would you happen to have any thoughts on why there might be a delay? Thanks so much for all of the information and guidance you provide

Categories: NIH-Funding

Tissue Mapping Centers for the Human BioMolecular Atlas Program (U54 Clinical Trials Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 04:50
Funding Opportunity RFA-RM-17-027 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish state-of-the-art Tissue Mapping Centers (TMCs) that will generate high-resolution, multi-parameter maps of non-diseased human organs and systems. Centers will be expected to integrate and optimize all parts of the data generation pipeline, from tissue collection and preservation through to data integration, analysis and interpretation. Centers will also be expected to work closely with the other funded projects as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with micron resolution.
Categories: NIH-Funding

Transformative Technology Development for the Human BioMolecular Atlas Program (UG3/UH3 Clinical Trials Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 04:50
Funding Opportunity RFA-RM-17-025 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit transformative technologies that will significantly expand throughput, multiplexing and discrimination of biomolecules in human tissues for comprehensive mapping of individual cells and their context in human tissues. This FOA supports the accelerated proof-of-principle demonstration and validation of promising tools, techniques and systems that can be integrated, scaled and applied to multiple human tissues. The initial two-year UH2 phase will support accelerated development and demonstration of feasibility of these emerging, high impact technologies. The subsequent two-year UH3 phase will support validation in human tissues, optimization, scale-up, and generation of initial production level data. Funded projects will be expected to work closely as part of the Human BioMolecular Atlas Program to catalyze development of a framework for mapping the human body with high resolution.
Categories: NIH-Funding

Consequences of amyloid protein polymorphisms in Alzheimer's disease (R01 - Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 04:06
Funding Opportunity RFA-AG-18-025 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the consequences of amyloid protein polymorphism in regulation and initiation of early pathogenesis in Alzheimers disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of biochemical and cellular pathways that are responsible for the differential accumulation of various protein conformers in AD clinical subtypes.
Categories: NIH-Funding

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R03 Clinical Trial Optional)

NIH Funding Announcements - Mon, 12/18/2017 - 04:01
Funding Opportunity PAR-18-527 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.
Categories: NIH-Funding

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R01 )

NIH Funding Announcements - Mon, 12/18/2017 - 04:01
Funding Opportunity PAR-18-510 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.
Categories: NIH-Funding

Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects (R21 Clinical Trial Optional )

NIH Funding Announcements - Mon, 12/18/2017 - 04:01
Funding Opportunity PAR-18-509 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.
Categories: NIH-Funding

Innovative Questions in Symptom Science and Genomics (R15 Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 03:49
Funding Opportunity PA-18-471 from the NIH Guide for Grants and Contracts. This initiative seeks to optimize innovation, insight and cutting edge conceptual and technological breakthroughs by catalyzing research that emanates from the identified innovative questions in symptom and genomic nursing science. These innovative questions are reflective of broad domains from which more specific novel hypotheses or problems to be solved can be derived.
Categories: NIH-Funding

Personalized Strategies to Manage Symptoms of Chronic Illness (R15 Clinical Trial Not Allowed)

NIH Funding Announcements - Mon, 12/18/2017 - 03:49
Funding Opportunity PA-18-472 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms.
Categories: NIH-Funding

Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)

NIH Funding Announcements - Mon, 12/18/2017 - 02:44
Funding Opportunity PAR-18-513 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to develop and implement Phase I to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age-related dementias using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure.
Categories: NIH-Funding